Results 31 to 40 of about 32,890 (266)

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience

Clinical, Cosmetic and Investigational Dermatology, 2023
To date, adalimumab (ADA) is the only biotechnology drug approved for the management of hidradenitis suppurativa (HS), an inflammatory skin condition.
F. Martora, M. Megna, T. Battista, L. Potestio, M. C. Annunziata, C. Marasca, A. Villani, G. Fabbrocini   +7 more
semanticscholar   +1 more source

Ustekinumab for the treatment of psoriatic arthritis: an update. [PDF]

, 2014
Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic ...
Davari, Parastoo, Fazel, Nasim, Kamangar, Faranak, Leo, Michael S   +3 more
core   +1 more source

Ustekinumab treatment and improvement of physical function and health‐related quality of life in patients with psoriatic arthritis [PDF]

, 2016
Objective: Examine ustekinumab effects on patient-reported outcomes (PROs) in PSUMMIT-1/PSUMMIT-2 patients with active psoriatic arthritis (PsA) who were methotrexate (MTX)-naïve, MTX-experienced, or anti-tumor necrosis factor (TNF)-experienced ...
Dalal, Ekelund, Feldman, Finlay, Fries, Gupta, Husted, Husted, Kavanaugh, Kimball, Koo, McInnes, Mease, Puig, Ritchlin, Schünemann, Tillett, Walsh, Ware   +18 more
core   +1 more source

Real‐life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104‐week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS)

Journal of the European Academy of Dermatology and Venereology, 2023
Guselkumab is a fully human monoclonal antibody that binds selectively to the p19 subunit of interleukin‐23, which has shown efficacy in patients with previous incomplete response to ustekinumab in the NAVIGATE clinical trial. [Correction added on [28‐02‐
L. Gargiulo, L. Ibba, P. Malagoli, R. G. Angileri, F. Bardazzi, N. Bernardini, M. Burlando, C. Carrera, A. Chiricozzi, P. Dapavo, V. Dini, G. Fabbrocini, F. Gaiani, M. Galluzzo, C. Giofré, C. Guarneri, F. Loconsole, G. Malara, Lorenzo Marcelli, M. Megna, S. Piaserico, M. Talamonti, A. Costanzo, A. Narcisi   +23 more
semanticscholar   +1 more source

Effectiveness and safety of ustekinumab for the treatment of psoriasis; six years of clinical experience

Journal of Dermatological Treatment, 2023
Background This work aimed to investigate the long-term clinical experience with ustekinumab in cases with psoriasis. Materials and methods This retrospective cohort research group consisted of cases who presented to the dermatology outpatient clinics ...
Melis Gönülal, Didem Didar Balcı, Aylin Öztürk, Sinan Doğan   +3 more
doaj   +1 more source

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial [PDF]

, 2014
Objective: Assess ustekinumab efficacy (week 24/week 52) and safety (week 16/week 24/week 60) in patients with active psoriatic arthritis (PsA) despite treatment with conventional and/or biological anti-tumour necrosis factor (TNF) agents. Methods: In
Alten, R., Birbara, C., Boh, E., Braun, J., Budd, J., Chattapadhyay, C., Chudzik, D., Claudepierre, P., Cooper, R., Dooley, L. T., Doyle, M. K., Drescher, E., Dutz, J., Edwards, C., El-Kadi, H., Elewski, B., Erlacher, L., Flipo, R., Fretzin, S., George, E., Gladstein, G., Gottlieb, A. B., Griffin, R., Grisanti, M., Guenther, L., Gulliver, W., Hobbs, K., Huang, E., Ilivanova, E., Jeka, S., Kavanaugh, A., Khraishi, M., Kokhan, M., Korman, N., Kunynetz, R., Leonardi, C., Lessard, C., Li, S., Lindquist, U., Martin, A., Matheson, R., McInnes, I.B., Mendelsohn, A. M., Murphy, F., Nasonov, E., Palmer, W., Papp, K., Perate, M., Puig, L., Rahman, P., Rech, J., Rell-Bakalarska, M., Rich, P., Ritchlin, C., Rosen, C., Rudin, A., Ruppert-Roth, A., Scheinecker, C., Seigel, S., Shaikh, S., Sheeran, T., Shen, Y.-K., Shergy, W., Siegel, E., Sierakowski, S., Sofen, H., Szanto, S., Tahir, H., Telegdy, E., Toth, D., Walker, D., Wang, Y., Whitman, M., Wilson, A., Witt, M., Wollenhaupt, J., Zoschke, D., Zubrzycka, A.   +77 more
core   +1 more source

Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.

The Lancet Gastroenterology and Hepatology, 2022
BACKGROUND A treat-to-target strategy, in which strictly defined treatment targets facilitate decision making in clinical practice, is advocated as an optimised management approach for some chronic disorders.
S. Danese, S. Vermeire, G. D'Haens, J. Panés, A. Dignass, F. Magro, M. Nazar, M. le Bars, M. Lahaye, L. Ni, I. Bravatá, F. Lavie, M. Daperno, M. Lukáš, A. Armuzzi, M. Löwenberg, D. Gaya, L. Peyrin-Biroulet   +17 more
semanticscholar   +1 more source

Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study

American Journal of Gastroenterology, 2023
INTRODUCTION: Ulcerative colitis (UC) is a chronic condition that may require long-term treatment. We report the final efficacy and safety results of the UNIFI long-term extension study of ustekinumab in patients with UC through 4 years.
W. Afif, Ramesh P. Arasaradnam, M. Abreu, S. Danese, W. Sandborn, Y. Miao, Hongyan Zhang, R. Panaccione, T. Hisamatsu, Ellen Scherl, Rupert Leong, D. Rowbotham, L. Peyrin-Biroulet, B. Sands, C. Marano   +14 more
semanticscholar   +1 more source

Hepatitis B Virus Reactivation and Mycobacterial Infections Associated With Ustekinumab: A Retrospective Study of an International Pharmacovigilance Database

Frontiers in Pharmacology, 2022
Background: Reports were recently published on hepatitis B virus reactivation (HBVr), tuberculosis (TB), and atypical mycobacterial infection (AMI) in patients with ustekinumab treatment. However, the literature is limited to case reports and series. The
Jingjing Wang, Xiaozhen Geng, Xin Zhang, Yanfeng Xiao, Wenjun Wang   +4 more
doaj   +1 more source

Secukinumab in the treatment of psoriasis: patient selection and perspectives. [PDF]

, 2018
Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Beck, Kristen M, Liao, Wilson, Yang, Eric J   +2 more
core   +1 more source